EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate